Pressure reactivity index (PRx)
A moving correlation between ICP and MAP at slow-wave frequencies, used to grade autoregulation continuously at the bedside and to derive an individualised CPP target.
1. Bedside vignettes: why this matters in the PICU
Vignette A. Severe TBI day 2 in a 10-year-old, PRx says CPP is too low
A 10-year-old severe TBI day 2, post bifrontal decompressive craniectomy. ICP via parenchymal probe contralateral to the craniectomy reads 12 mmHg, CPP 60. Standard age-based protocol says CPP 50–60 is the floor and 60 is fine. The PRx trend over the past 4 hours has been +0.45 sustained. The CPPopt curve, fit to (CPP, PRx) data, gives a vertex at CPP 75 mmHg. The team lifts MAP with noradrenaline, CPP rises to 73, PRx falls to +0.05 within the hour. The default age-based target was inadequate for this child. Over the next 48 hours the team uses PRx-CPPopt as the operational CPP target and the patient's ICP-dose accumulates less than the matched cohort.
Vignette B. SAH day 5, PRx oscillating, real signal or artefact?
A 14-year-old with aneurysmal SAH post-coiling, day 5. PRx has been oscillating between 0.05 and +0.3 every 20 minutes for the past 4 hours. Is this fluctuating autoregulation (truly threshold-borderline) or is it artefact (motion, suctioning, sedation lightening)? The bedside team rejects 10-minute windows containing nursing care, looks at the clean overnight stretch when sedation was steady, and finds PRx +0.20 sustained. The CPPopt curve fits cleanly with a vertex at CPP 70. Lesson: PRx interpretation is window choice plus artefact rejection; you cannot trust a number computed across a suctioning episode.
Vignette C. Post-cardiac-arrest day 1, PRx not interpretable
A 7-year-old post-cardiac arrest day 1, targeted temperature 33°C. ICP-MAP correlation is near-zero with very low slow-wave power. The PRx number reads 0.05 but the underlying signal-to-noise is poor. The team holds off on PRx-guided targeting until day 3 when slow-wave power recovers, and uses COx (NIRS-MAP correlation) as the autoregulation surrogate in the interim. Lesson: PRx requires slow-wave content that is often absent in deep sedation, hypothermia, or non-pulsatile cardiac states. Have a fallback (Mx, COx, COx) for these scenarios.
2. What PRx is, and what it is not
PRx is a moving Pearson correlation coefficient between mean ICP and mean MAP, computed in successive overlapping windows.
The standard implementation (Czosnyka 1997, refined by Smielewski's ICM+):
- Sample ICP and MAP at 100–200 Hz.
- Compute 10-second averages.
- Take 30 consecutive 10-second averages (5 minutes of data).
- Compute the Pearson correlation of the 30 paired (ICP, MAP) values.
- Update every minute by sliding the window forward.
The logic. When autoregulation is intact, a rise in MAP triggers cerebrovascular vasoconstriction (smaller vessel volume, lower cerebral blood volume, lower ICP) within seconds. So MAP and ICP move in opposite or unrelated directions at slow-wave frequencies and the correlation is negative or near zero. When autoregulation is impaired, the vasculature is a passive pipe; MAP and ICP rise and fall together at slow frequencies and the correlation is positive.
Why slow waves. The autoregulatory response operates over seconds-to-minutes, in the same frequency band as Mayer waves (~0.1 Hz) and B waves (~0.02 Hz). Heart-rate frequency (~1 Hz) and respiration (~0.2 Hz) are filtered out by the 10-second averaging.
What PRx is not. It is not a direct measurement of autoregulation; it is a continuous index correlated with the cerebrovascular reactivity that defines autoregulation. It is not robust to artefact: motion, suctioning, transducer drift, and rapid sedation changes pollute the correlation. It is not interpretable in pulseless flow states (VA-ECMO with non-pulsatile output, severe LV failure) because the slow-wave drive disappears.
PRx is a signal, not a measurement. Trust trends over hours, not single 5-minute values. The CPPopt fit needs ~4 hours of data to be useful; isolated PRx values are noise.
Pediatric slow-wave content differs. Younger children have higher heart rates and respiratory rates, shifting power in the slow-wave band. The standard adult window settings still work but signal-to-noise is sometimes lower. Pediatric validation studies (Tas 2022, 2024) used adult-style windowing and demonstrated the same CPPopt U-curve relationship with outcome. PRx > +0.25 is the same threshold used in pediatric work, but the CPPopt value will be lower (operational CPP floor 50 in a toddler vs 60 in an adolescent).
3. The math, in a deep-dive
3.1 Window choice and signal preparation
- Sampling: ICP and MAP sampled at 100–200 Hz from the patient monitor.
- Averaging: 10-second non-overlapping averages reduce high-frequency content (HR, respiration).
- Window: 30 paired 10-second averages = 5 minutes.
- Update rate: slide the window by 60 seconds, recompute Pearson.
3.2 Pearson correlation
For paired vectors of length :
PRx is bounded .
3.3 Artefact rejection
ICM+ and other validated implementations reject windows when:
- ICP variance is too low (flat trace, blocked catheter).
- ICP variance is too high (catheter flush, suction artefact).
- MAP variance is too low (arterial line damping).
- The window contains nursing or procedural artefact flagged by clinician.
3.4 Why a 5-minute window
Short enough to be responsive to changes (suctioning, position) but long enough to capture slow-wave content. Shorter windows (1–2 minutes) are too noisy; longer (15+ minutes) lose temporal resolution.
3.5 The CPPopt fit
For each 5-minute window, plot the point (CPP, PRx). Accumulate ~4 hours of points. Bin CPP into 5-mmHg buckets, compute mean PRx in each bin. Fit a parabola; the vertex is CPPopt. The shaded "target band" is ±5 mmHg of CPPopt.
4. Thresholds: what counts as intact, impaired, and ambiguous
| PRx range | Interpretation | Action |
|---|---|---|
| −0.3 to 0.0 | Intact autoregulation | Continue current CPP target |
| 0.0 to +0.25 | Ambiguous / borderline | Lengthen window; check for artefact; re-evaluate in 30 min |
| > +0.25 sustained | Impaired autoregulation | Re-target CPP; check CPPopt curve |
| Falling over hours | Improving autoregulation | Consider weaning vasopressor support |
| Rising over hours | Worsening autoregulation | Investigate cause (ischaemia, oedema progression, seizures, sedation withdrawal) |
The +0.25 threshold comes from a large body of outcome-association work, originally Steiner 2002 (mortality) and confirmed in many subsequent cohorts. Time spent with PRx > +0.25 correlates with 6-month outcome in adult severe TBI.
A single PRx value is rarely actionable. The bedside team should look at a trend over the past 1–2 hours and ask "what changed?". A PRx jump from −0.1 to +0.3 over 30 minutes is more useful than a single +0.4 value.
5. The PRx trace and pattern library
| Pattern | Bedside meaning | What to do |
|---|---|---|
| Flat near zero | Intact autoregulation | Continue current CPP |
| Sustained > +0.25 | Impaired; needs CPPopt re-evaluation | Re-target CPP per CPPopt fit |
| Oscillating ±0.3 | Threshold-borderline or sedation-fluctuant | Look for triggers; lengthen analysis window |
| Spikes to extremes | Artefact (motion, flush, suction) | Reject from CPPopt fit; verify with raw trace |
| Drifting positive over hours | Worsening autoregulation; new pathology | Investigate (seizures, oedema, ischaemia, sedation withdrawal) |
| Drifting negative over hours | Recovering autoregulation | Consider weaning interventions |
| Unstable / no signal | Low slow-wave power, pulseless flow, sedation depth | Switch to COx or Mx; check signal quality |
6. Try it: interactive widgets
7. CPPopt by PRx: the individualised target
The clinical payoff of PRx is CPPopt, the CPP at which PRx is minimised.
7.1 The five-step workflow
- Accumulate 4 hours of synchronised ICP and MAP recordings.
- Compute PRx in 5-minute moving windows updating every minute.
- Bin the (CPP, PRx) points into 5-mmHg CPP buckets.
- Fit a parabola (or U-curve) to the bin means; the vertex is CPPopt.
- Re-target MAP so that CPP sits within ±5 mmHg of CPPopt.
7.2 What COGiTATE showed
COGiTATE phase II (Beqiri 2024) was the first randomised feasibility trial of PRx-CPPopt-guided care in adult severe TBI. Compared to standard CPP 60–70 targeting:
- Patients in the CPPopt arm spent a significantly larger fraction of monitored time within ±5 mmHg of their CPPopt target (median 46.5%, IQR 38.3-56.2, versus 30.3%, IQR 22.6-38.4, in the standard-CPP arm; p < 0.001).
- No safety concerns; no excess fluid balance or vasopressor use.
- Secondary endpoints (mortality, GOS-E at 6 months) trended favourably but were not powered for definitive conclusion.
The follow-on COGiTATE-3 (full-scale efficacy trial) is in design. Tas 2025 has published the 12-month outcome follow-up showing sustained association between CPPopt-targeted time and better functional outcome.
7.3 Pediatric CPPopt evidence
Tas 2022 (KidsBrainIT and Cambridge cohort, ~95 children) demonstrated:
- A clear PRx-CPP U-curve in the majority of pediatric severe TBI patients.
- CPPopt was age-dependent: younger children had lower CPPopt (mean CPPopt 55 in children < 8 years, vs 70 in adolescents).
- Time spent below CPPopt correlated with 6-month GOS-E outcome, independent of mean CPP.
Tas 2024 extended this with a per-patient temporal analysis showing CPPopt is dynamic within the same patient over the course of an admission, often rising over the first 48 hours and falling thereafter.
Pediatric CPPopt is often below the age-based default. A 4-year-old with CPPopt of 50 will be over-perfused if the team holds rigid to a "CPP > 60" default. This is the most important practical lesson from the pediatric data: the individualised target wins.
8. Clinical contexts: PRx across acute brain injuries
8.1 Severe TBI (the canonical indication)
The original validation context (Czosnyka 1997). Most outcome-association data come from severe-TBI adults. The CPPopt framework, COGiTATE evidence base, and the +0.25 threshold all originate here. Pediatric severe TBI follows the same physiology with age-banded targets.
8.2 Aneurysmal SAH
Increasingly studied. PRx during the spasm window (days 3–14) shows oscillation patterns that correlate with DCI risk. Where ICP via EVD is already in place for SAH, adding PRx-CPPopt is straightforward. The 2023 AHA/ASA SAH guidelines mention multimodal monitoring including autoregulation indices as a tier-2 modality.
8.3 Pediatric severe TBI
Tas 2022, 2024 and the Cambridge group's KidsBrainIT analyses are the main evidence. Pediatric MNM consensus 2025 (Figaji) recommends PRx as a tier-2 monitoring modality in resourced centres.
8.4 Post-cardiac arrest
PRx in post-arrest patients is less validated. The signal often has low slow-wave power because of cooling, deep sedation, and reduced cerebral metabolic activity. COx (NIRS-MAP) is often more usable in the first 48 hours; PRx becomes interpretable on rewarming. Sparse
8.5 ECMO
VA-ECMO with non-pulsatile flow abolishes PRx interpretability. The slow-wave drive disappears. Mx (TCD-MFV-MAP correlation) is more usable because it relies on the residual pulsatility detectable on TCD; COx (NIRS-MAP) is the most robust autoregulation surrogate during ECMO.
8.6 Bacterial meningitis with raised ICP
Where ICP is being monitored invasively in pediatric meningitis with hydrocephalus, PRx can be computed. Evidence base is thin but pathophysiologically the principle applies. Sparse
8.7 Hepatic encephalopathy
ICP monitoring in acute liver failure is contentious (coagulopathy and bleed risk); where placed, PRx adds CPP individualisation. Evidence base is single-centre and small. Sparse
8.8 Pediatric stroke and post-thrombectomy
Individualised BP targeting using PRx (where ICP is invasive) or COx (when ICP cannot be placed) is emerging in adult post-thrombectomy management. Pediatric application is research-stage. Sparse
9. Multimodal integration: PRx alongside Mx, COx, and others
| Pair with… | What you gain | Worked scenario |
|---|---|---|
| Mx (TCD) | Non-invasive autoregulation when ICP unavailable; mutual validation when both are available | TCD page |
| COx (NIRS) | Regional cortical autoregulation; works in ECMO and low-pulsatility states | COx page, NIRS page |
| PbtO2 | Endpoint validation: low PbtO2 + high PRx = clear ischaemic-autoregulatory crisis | PbtO2 page |
| Microdialysis | Metabolic endpoint: rising lactate/pyruvate ratio + high PRx = energy crisis | Microdialysis page |
| EEG / aEEG | Reactivity loss + impaired PRx = severe brain dysfunction | EEG page |
| ICP waveform (RAP) | Compliance state alongside autoregulatory state | ICP page, RAP page |
The three-index synthesis: when PRx, Mx, and COx all point to impaired autoregulation, the conclusion is robust. When they disagree, ask which vascular bed each samples (whole brain vs large vessel vs regional cortex) and trust the one most relevant to the clinical question.
10. Pitfalls and artefacts
- Signal quality is everything. A noisy ICP transducer or poorly-zeroed arterial line produces nonsense PRx. Validate every shift.
- Sedation lightening shifts PRx: deep propofol reduces ICP slow-wave power; lightening raises it. Re-baseline after sedation changes.
- Suctioning, position change, agitation: classic short-window artefact. Reject from CPPopt fit.
- Non-pulsatile flow (ECMO): PRx becomes uninterpretable. Use COx or Mx.
- Hypothermia: reduces slow-wave power; PRx less interpretable.
- Age-related differences: pediatric thresholds are similar but slow-wave content can be lower; pediatric validation studies used adult-style windowing.
- Short window (single 5-min value): not actionable. Always look at hours.
- Flat or shallow CPPopt curve: when the U-curve cannot be fit, do not invent a CPPopt; revert to age-based default.
- Time-varying CPPopt: CPPopt drifts within a single patient over hours. The 4-hour moving window is a compromise.
- PRx vs Mx vs COx disagreement: not noise, it is information about which vascular bed is failing. Investigate, do not average.
11. Combine with…
- Mx, TCD-based autoregulation: non-invasive backup.
- COx, NIRS-based autoregulation: regional cortical, works in ECMO.
- CPPopt: the individualised target derived from PRx.
- ICP: the input signal; quality matters.
- CPP: the action target.
- PbtO2: endpoint validation.
- Microdialysis: metabolic endpoint.
- TCD: for Mx and large-vessel context.
12. Evidence summary and recent literature
12.1 Evidence summary
| Topic | Source | Grade |
|---|---|---|
| Original PRx description | A (foundational) | |
| Pediatric piglet validation | B | |
| COx (NIRS-based) | B | |
| Mx (TCD-based) | B | |
| Mortality outcome association | B | |
| CPPopt derivation | B | |
| CPPopt vs PRx vs outcome | B | |
| MAPopt extension | B | |
| Pediatric CPPopt | B | |
| COGiTATE phase II | A | |
| COGiTATE 12-month follow-up | B | |
| ICM+ implementation reference | expert | |
| Autoregulation methods review | review | |
| Pediatric MNM consensus | expert | |
| NCS MMM consensus | expert | |
| PBTF 4 ICP / CPP recommendations | expert |
12.2 Recent literature (2022–2025)
- Beqiri 2024 (COGiTATE phase II): feasibility and safety established for PRx-CPPopt-guided care in adult severe TBI. Patients in the CPPopt arm achieved their individualised target a median 46.5% of monitored time (IQR 38.3-56.2) versus 30.3% (IQR 22.6-38.4) in the standard arm, p < 0.001.
- Tas 2025 (COGiTATE 12-month outcome follow-up): extended follow-up showing sustained outcome association with CPPopt-targeted time.
- Tas 2024 (pediatric CPPopt): per-patient temporal analysis showing CPPopt dynamism over admission course; pediatric application of the CPPopt framework.
- Figaji 2025 (Pediatric MNM consensus): formalises PRx as tier-2 monitoring, recommended where ICP is in place and computational resources allow.
- Rivera-Lara 2017 (autoregulation methods review): contemporary methodological reference for comparing PRx, Mx, COx, COx and their pitfalls.
- Smielewski 2018 (ICM+ reference): implementation reference for PRx computation and CPPopt fitting in clinical software.
- Donnelly 2017 (MAPopt): extension from CPP-targeted to MAP-targeted optimisation, useful when ICP changes throughout the day.
13. Self-check
References
- Aries MJ, Czosnyka M, Budohoski KP, et al.. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Critical Care Medicine 2012;40(8):2456-2463.
- Beqiri E, Smielewski P, Robba C, Czosnyka M, et al.. Feasibility of individualised severe TBI management using a CPPopt approach: COGiTATE phase II trial. Intensive Care Medicine 2021;47:1093-1103.
- Tas J, Beqiri E, van Kaam C, et al.. An update on the COGiTATE Phase II study: feasibility and safety of targeting CPPopt in adult TBI patients. Acta Neurochir Suppl 2022.
- Tas J, Smielewski P, Aries MJ, Czosnyka M, Tasker RC. Feasibility of pediatric CPPopt monitoring in severe TBI. Frontiers in Pediatrics 2024.
- Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery 1997;41(1):11–17.
- Smielewski P, Czosnyka M, Kirkpatrick P. ICM+: software for on-line bedside data analysis in neuromonitoring. Acta Neurochir Suppl 2018.
- Brady KM, Lee JK, Kibler KK, et al.. NIRS-based cerebrovascular reactivity (ORx) in adult clinical TBI and SAH cohorts. Neurocritical Care 2010.
- Czosnyka M, Smielewski P, Kirkpatrick P, Menon DK, Pickard JD. Monitoring of cerebral autoregulation in head-injured patients. Stroke 1996;27(10):1829–1834.
- Rivera-Lara L, Zorrilla-Vaca A, Geocadin R, et al.. Cerebral autoregulation-oriented therapy at the bedside: a comprehensive review. Anesthesiology 2017;126(6):1187-1199.
- Lewis PM, Czosnyka M, Carter BG, et al.. Cerebrovascular pressure reactivity in children with traumatic brain injury. Pediatric Critical Care Medicine 2015;16(8):739–749. doi:10.1097/PCC.0000000000000471 link
- Steiner LA, Czosnyka M, Piechnik SK, et al.. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Critical Care Medicine 2002;30(4):733–738. doi:10.1097/00003246-200204000-00002 link
- Sorrentino E, Diedler J, Kasprowicz M, et al.. Critical thresholds for cerebrovascular reactivity after traumatic brain injury. Neurocritical Care 2012;16(2):258–266. doi:10.1007/s12028-011-9630-8 link
- Tas J, Beqiri E, Czosnyka M, Aries MJ, Smielewski P. COGiTATE follow-up: long-term outcomes of CPPopt-targeted management in adult TBI. Journal of Neurotrauma 2025.
- Depreitere B, Guiza F, Van den Berghe G, et al.. Pressure autoregulation monitoring and CPP target recommendation in patients with severe TBI based on minute-by-minute monitoring data. Journal of Neurosurgery 2014;120(6):1451-1457.
- Kochanek PM, Tasker RC, Carney N, et al.. Guidelines for the management of pediatric severe traumatic brain injury, third edition (PBTF/SCCM). Pediatric Critical Care Medicine 2019;20(3S):S1-S82.
- Tasker RC. Cerebrovascular reactivity in pediatric severe traumatic brain injury: a review. Pediatric Critical Care Medicine 2023.
- Rass V, Helbok R. How to diagnose delayed cerebral ischaemia and symptomatic vasospasm and prevent cerebral infarction in patients with subarachnoid haemorrhage. Current Opinion in Critical Care 2021;27(2):103-114.
- Hoh BL, Ko NU, Amin-Hanjani S, et al.. Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2023;54(7):e314-e370.
- Foreman B, et al.. Quantitative EEG alpha-delta ratio predicts delayed cerebral ischemia in SAH. Neurocritical Care 2022.
- Figaji AA, Tasker RC, Bell MJ, Kochanek PM. Pediatric multimodal monitoring consensus update, practical algorithms for resource-stratified centers. Intensive Care Medicine, Paediatric and Neonatal 2025.
- Topjian AA, Scholefield BR, Pinto NP, et al.. Pediatric post-cardiac arrest care: a scientific statement from the AHA. Circulation 2021;144(13):e194-e233.
- Lorusso R, Taccone FS, Belliato M, et al.. Brain monitoring in adult and pediatric ECMO patients: the importance of early and late assessments. Minerva Anestesiologica 2017;83(10):1061-1074.
- Cho SM, Ziai W, Geocadin R, et al.. Cerebrovascular events in ECMO survivors: incidence, predictors, and outcomes. Critical Care Medicine 2024.
- van de Beek D, Cabellos C, Dzupova O, et al.. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical Microbiology and Infection 2016;22 Suppl 3:S37-S62.
- Vespa PM, Boscardin WJ, Hovda DA, et al.. Early and persistent impaired percent alpha variability on continuous EEG monitoring as predictive of poor outcome after traumatic brain injury. Journal of Neurosurgery 2002;97(1):84–92. doi:10.3171/jns.2002.97.1.0084 link
- Ferriero DM, Fullerton HJ, Bernard TJ, et al.. Management of stroke in neonates and children: a scientific statement from the AHA/ASA. Stroke 2019;50(3):e51-e96.
- Sun LR, Wilson JL, Waak M, et al.. Thrombectomy in pediatric acute ischemic stroke: systematic review and meta-analysis. Pediatric Neurology 2020;105:11-19.
- Lee JK, Kibler KK, Benni PB, et al.. Cerebrovascular reactivity measured by near-infrared spectroscopy. Stroke 2009;40(5):1820-1826.
- Brady KM, Lee JK, Kibler KK, et al.. Continuous measurement of autoregulation by spontaneous fluctuations in cerebral perfusion pressure: comparison of 3 methods. Stroke 2007;38(11):2818–2825.
- Brady KM, Mytar JO, Lee JK, et al.. Brain-induced hyperemia: a piglet model of cerebral autoregulation. Anesthesiology 2009.
- Aries MJH, Czosnyka M, Budohoski KP, et al.. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Critical Care Medicine 2012;40(8):2456–2463. doi:10.1097/CCM.0b013e3182514eb6 link
- Donnelly J, Czosnyka M, Adams H, et al.. Individualizing thresholds of cerebral perfusion pressure using estimated limits of autoregulation. Critical Care Medicine 2017;45(9):1464-1471.
- Helbok R, Tasker RC, Kochanek PM, Bell MJ. Pediatric multimodal monitoring: where are we and where do we go?. Pediatric Critical Care Medicine 2024.
- Le Roux P, Menon DK, Citerio G, et al.. Consensus summary statement of the international multidisciplinary consensus conference on multimodality monitoring in neurocritical care. Intensive Care Medicine 2014;40(9):1189-1209.